Nanobiotix is a clinical-stage biotech developing nanomedicine for oncology, centered on radioenhancer nanoparticles designed to amplify radiotherapy’s effect in tumors. Its lead approach uses hafnium oxide particles injected into tumors and activated by standard radiation. The company targets solid cancers where improving local radiation response is a key clinical goal.
| Year | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| 2022 | 0 | — | -57 | — |
| 2023 | 30.1 | — | -39.7 | — |
| 2024 | -11.6 | -138.6% | -68.1 | — |
| 2025 | 29.6 | — | -24 | — |
All markets — KeepWinning global stock screener
Other companies on Euronext Paris: OPmobility SE (OPM), Louis Hachette Group S.A. (ALHG), Caisse Régionale de Crédit Agricole Mutuel du Languedoc Société coopérative (CRLA), Caisse Régionale de Crédit Agricole Mutuel Nord de France Société coopérative (CNDF), Planisware SAS (PLNW), Robertet SA (RBT)